Simplify Asset Management Inc. Takes $700,000 Position in Upstream Bio, Inc. $UPB

Simplify Asset Management Inc. purchased a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 77,793 shares of the company’s stock, valued at approximately $700,000. Simplify Asset Management Inc. owned about 0.14% of Upstream Bio as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. lifted its position in shares of Upstream Bio by 6.4% in the second quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock valued at $179,000 after buying an additional 985 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $29,000. Torren Management LLC acquired a new position in shares of Upstream Bio during the 4th quarter worth approximately $30,000. JPMorgan Chase & Co. grew its position in Upstream Bio by 8.4% during the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after buying an additional 1,275 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts recently issued reports on UPB shares. JPMorgan Chase & Co. cut shares of Upstream Bio from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $35.00 to $8.00 in a research note on Friday, June 12th. Mizuho decreased their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen downgraded Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Evercore downgraded shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target on the stock. in a research note on Friday, March 27th. Finally, Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $33.17.

Upstream Bio Price Performance

Upstream Bio stock opened at $7.51 on Friday. The business has a 50 day moving average of $7.79 and a 200-day moving average of $14.62. The company has a market capitalization of $408.69 million, a P/E ratio of -2.58 and a beta of 1.23. Upstream Bio, Inc. has a 1 year low of $5.85 and a 1 year high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. Equities analysts anticipate that Upstream Bio, Inc. will post -2.9 EPS for the current year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.